Meridian Bioscience Osake

Meridian Bioscience P/B

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Meridian Bioscience (VIVO) 22.7.2026 päivämäärällä on 4,06. Edellisenä vuonna P/B (Hinta-kirjanpitoarvo-suhde) oli 4,55 — muutos −10,80 % (matalampi).

P/B

4,06

YoY

−10,80%

Viimeksi päivitetty:

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Meridian Bioscience on 2026 4,06 . P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Meridian Bioscience oli 2025 4,55 . Se laskee −10,80% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Meridian Bioscience Osakeanalyysi

Mitä Meridian Bioscience tekee? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Meridian Bioscience osakkeesta

Yhtiön Meridian Bioscience P/B (Hinta-kirjanpitoarvo-suhde) on 4,06 vuonna 2026.

Access this data via the Eulerpool API

Arvostus — Meridian Bioscience

Kaikki tunnusluvut — Meridian Bioscience